Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer
European Urology, 04/23/2012Agarwal N et al.
The approval of agents for advanced prostate cancer underscores the importance of androgen pathway inhibition, immunotherapy, tubulin antagonists, and pathophysiology of bone metastasis. Trials are also targeting pathways that modulate invasion, and angiogenesis.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.